Acción BIOR BIORA THERAPEUTICS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Biora Therapeutics, Inc.

Acciones

BIOR

US74319F3055

Tiempo real estimado Cboe BZX
Otros sitios de cotización
 21:36:57 30/04/2024 		Varia. Cinco días. Varia. 1 de enero.
0,639 USD +2,65 % Gráfico intradía de Biora Therapeutics, Inc. -1,39 % -53,33 %
04/04 Biora Therapeutics, Inc. Logra resultados provisionales positivos en el ensayo clínico de BT-600 y avanza en el desarrollo de la plataforma NaviCap CI
03/04 Athyrium Capital Management entabla conversaciones con Biora Therapeutics CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600
Biora Therapeutics : Form 8937 – Convertible Note Exchange (December 19, 2023)
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Athyrium Capital Management Engages in Discussions with Biora Therapeutics
Top Midday Decliners
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Biora Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose Cohorts of Phase 1 Clinical Study of BT-600
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
Biora Therapeutics Provides Outlook for 2024
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción BIOR
  4. Noticias Biora Therapeutics, Inc.
  5. Otros idiomas